According to GRADE and EBM methodology, here is what ideal scientific evidence would look like to definitively prove or disprove this specific claim, ordered from strongest to weakest evidence.
Randomized Controlled Trial
A randomized controlled trial enrolling women aged 40–70 in the UK with no prior estrogen therapy, randomly assigning them to receive one of the specified estrogen therapies (estradiol, estraderm, vagifem, estriol) or placebo, with follow-up for at least 5 years to measure all-cause mortality, while controlling for age, smoking status, cancer history, and diabetes. A prospective cohort study using UK electronic health records (e.g., UK Biobank or CPRD) tracking women aged 40–70 who were newly prescribed one of the specified estrogen therapies versus those never prescribed them, with follow-up for all-cause mortality over 5–10 years, adjusting for age, smoking, cancer, and diabetes as confounders. Nested Case-Control Study
A nested case-control study within a UK cohort of women aged 40–70, identifying women who died from any cause during follow-up (cases) and matched living controls, then comparing their prior exposure to estrogen therapies (estradiol, estraderm, vagifem, estriol) while adjusting for age, smoking, cancer, and diabetes. A cross-sectional analysis comparing mortality rates between women aged 40–70 in the UK currently prescribed estrogen therapies versus those not, using population-level data, adjusting for age, smoking, cancer, and diabetes. An ecological study comparing regional mortality rates in the UK with regional rates of estrogen therapy prescriptions among women aged 40–70, adjusting for population-level smoking, cancer, and diabetes prevalence.